Insider buying last 90 days
No open-market insider purchases were filed for GRFS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GRFS insider filing, plotted on the chart in Gekko.Open GRFS in Gekko
Gekko Brief
AI summaryThis week's news centers on Grifols' first-half results and a regulatory issue in its plasma network. The company reported first-half revenue of EUR 3.6 billion and adjusted EBITDA of EUR 854 million, with net profit rising 28.7% to EUR 227 million and free cash flow turning positive, which lifted shares 2.06%. Separately, Health Canada suspended the license of Grifols' Winnipeg facility over quality management deficiencies; Grifols has stated this will not impact ongoing operations. The stock also saw declines tied to its removal from the S&P International 700 and S&P Europe 350 pharmaceuticals indices.
GRFS closed at $7.41, down from both its 50-day average of $7.75 and 200-day average of $8.19, with the 50-day below the 200-day. Shares are off 24.1% over the past year, though up 1.1% over three months. The GekkoIndex reads 63.9, placing the stock in the Accumulation zone. Price sits 41.7% below Gekko Fair Value of $12.72.
Over the next 20 trading days, no insider, Congress, or unusual options activity appears in the respective windows. The next earnings report is set for 10 November 2026, 42 days out, placing it beyond a typical holding period. Historically, the next 20 trading days from this point in the calendar averaged a decline of 5.9% over five years, higher in just one of those years. Analyst consensus targets $10.87.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Grifols price vs fair value
Close $7.41200-day averageGekko Fair Value $12.72
Grifols quick facts
- Market cap
- $6.27B
- P/E ratio
- 9.7
- Forward P/E
- 5.8
- EPS, TTM
- $0.76
- Revenue, TTM
- $7.42B
- Profit margin
- 6.1%
- Dividend yield
- —
- Beta
- 1.19
- Volume
- 597,118 avg 606,822
- 1-year return
- −24.1%
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±8.6%
- 50-day average
- $7.75
- 200-day average
- $8.19
- Next earnings
- Nov 10
- Shares outstanding
- 258.2M
Grifols swing-trade checklist
Grifols scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $7.41 is below the 50-day ($7.75) and 200-day ($8.19) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
63.9, Accumulation
Reading 63.9 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
41.7% below
Price is 41.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 42 days
Next report Nov 10, 2026, 42 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−5.9% on average
From this point in the calendar, the next 20 trading days averaged −5.9% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Grifols stock chart and price history
Grifols closed at $7.41 on Sep 28, 2026, −24.1% over the past year, inside a 52-week range of $6.96 to $10.23.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.2%
- 3 months
- +1.1%
- 6 months
- −1.1%
- 1 year
- −24.1%
The full GRFS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GRFS in Gekko
Follow Grifols through every session
Put GRFS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GRFS in GekkoFree for 7 days. No credit card required.
About Grifols
Grifols works mainly with human plasma, turning it into medicines used to manage serious and long-term illnesses. Among its most recognized products are immunoglobulins, alpha-1 antitrypsin, albumin and clotting factors, which help address conditions like hemophilia and problems with the immune system. The company also supplies hospitals with pharmaceutical items that are not biological in nature, along with medical devices, nutrition products for clinical settings and intravenous solutions.
Its business spans several distinct areas. One focuses on researching and marketing plasma-based treatments, another handles hospital-related supplies, and a further division builds diagnostic tools used at every stage of patient care, from early screening through to tracking treatment progress. A separate arm distributes biological materials needed for scientific research, clinical testing and the production of drugs and diagnostic goods. Buyers of these products include hospitals, blood banks, wholesalers, distributors, purchasing groups and both public and private health systems, and the company also works with Mondragon under a shared technology arrangement.
Grifols traces its origins to 1940 and runs its operations from Barcelona, Spain. Its stock can be found under the ticker GRFS.
- Sector
- Health technology
- Website
- grifols.com
Grifols GekkoIndex: the smart money zone
Grifols’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.9, in the Accumulation zone, down 2.7 points over five sessions.
63.9Accumulation
Down 2.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 22 | +4.8% | +8.2% | ||
| Accumulation (current zone) | 226 | +0.4% | +2.6% | ||
| Neutral | 326 | +0.1% | +0.1% | ||
| Distribution | 51 | −0.9% | −4.3% | ||
| Selling | 0 | Not available | |||
Average GRFS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the GRFS price, zone by zone.Track GRFS in Gekko
Is Grifols stock overvalued? Gekko Fair Value
Grifols trades 41.7% below Gekko Fair Value of $12.72, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Grifols shares are worth, recalculated every trading day.
$12.72
Gekko Fair Value, Sep 29, 2026
41.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open GRFS in Gekko
Grifols insider and Congress trading
No open-market insider purchases were filed for Grifols, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GRFS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GRFS, plotted on the chart in Gekko.Open GRFS in Gekko
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold GRFS.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Grifols earnings: next date and track record
Grifols reports on Nov 10, 2026 (42 days away), and beat the EPS estimate in 1 of its last 8 reports.
Next earnings report
Nov 10, 2026
42 days away
- EPS estimate
- $0.30
- Revenue estimate
- $2.29B
1 of 8reports beat the EPS estimate
±5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 7, 2026 AI summary
- What they said
- Grifols reported Q1 2026 revenue of EUR 1.7 billion, up 3.3% at constant currency. Adjusted EBITDA reached EUR 404 million at constant currency with margins broadly stable year-on-year. Biopharma grew nearly 7% at constant currency, driven by double-digit IG franchise growth. Leverage stood at 4.3x, and free cash flow improved EUR 30 million. Egypt EMA approval strengthens plasma diversification and reduces cost per liter.
- Guidance
- Grifols reaffirmed full-year 2026 guidance targeting adjusted EBITDA margins of at least 25%, 5%-9% adjusted EBITDA growth at constant currency, and free cash flow of EUR 500-575 million. Management expressed confidence results are tracking in line with expectations.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 7, 2026 | $0.13 est $0.15 | $2.00B est $2.03B | −3.7% |
| Feb 26, 2026 | $0.29 est $0.29 | $2.34B est $2.34B | −1.6% |
| Nov 4, 2025 | $0.21 est $0.24 | $2.14B est $2.15B | −8.5% |
| Jul 28, 2025 | $0.22 est $0.28 | $2.17B est $2.20B | +4.0% |
| May 12, 2025 | $0.09 est $0.16 | $1.99B est $1.96B | +10.7% |
| Mar 6, 2025 | $0.11 est $0.23 | — | −3.2% |
| Nov 7, 2024 | $0.17 est $0.24 | — | +4.9% |
| Jul 30, 2024 | $0.15 est $0.23 | — | −3.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Grifols stock forecast and analyst price targets
Analysts’ average 12-month price target for Grifols is $10.87, +46.7% from the last close.
$10.87consensus 12-month target, +46.7% from the last close
+2.6%average 20-day move after past Accumulation readings
−5.9%average move over the next 20 trading days in the last 5 years
±1.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Grifols seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Grifols averaged −5.9% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 1 of 5 |
| Next 10 trading days | −3.5% | 1 of 5 |
| Next 15 trading days | −5.0% | 1 of 5 |
| Next 20 trading days | −5.9% | 1 of 5 |
| Next 30 trading days | −1.0% | 2 of 5 |
For scale, GRFS’s typical 20-trading-day move in either direction is about 8.6%.
Grifols market cap and key statistics
Grifols’s market cap is $6.27B, with a P/E ratio of 9.7 and revenue of $7.42B over the last twelve months.
Valuation
- Market cap
- $6.27B
- P/E ratio
- 9.7
- Forward P/E
- 5.8
- EPS, TTM
- $0.76
- Gekko Fair Value
- $12.72
Trading
- Volume
- 597,118
- Avg volume, 20 days
- 606,822
- 52-week high
- $10.23
- 52-week low
- $6.96
- Shares outstanding
- 258.2M
Financials
- Revenue, TTM
- $7.42B
- Profit margin
- 6.1%
- Return on equity
- 6.9%
- Quarterly earnings growth, YoY
- +32.9%
Risk and income
- Beta
- 1.19
- Typical daily move
- ±1.9%
- Typical 20-day move
- ±8.6%
Grifols stock news this week
Coverage of Grifols this week reads neutral: 3 positive, 1 neutral and 3 negative headlines.
- Grifols stock gains 2.06 percent as profit jumpsAD HOC NEWS, Sep 28
- Grifols stock falls 3.09 percent to EUR 9.36 on BMEAD HOC NEWS, Sep 26
- Grifols stock falls 3.09 percent after index exitsAD HOC NEWS, Sep 25
- Grifols stock heads into the open after adding 0.43 percentAD HOC NEWS, Sep 25
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?Zacks Investment Research, Sep 24
- Grifols, S.A.Reuters, Sep 24
Grifols stock FAQ
What is Grifols’s market cap?
Grifols’s market cap is $6.27B at the Sep 28, 2026 close of $7.41, with 258.2M shares outstanding. The shares trade on a P/E ratio of 9.7.
What is the Grifols stock forecast?
The consensus analyst 12-month price target for Grifols is $10.87, +46.7% from the last close. Gekko doesn’t publish price predictions of its own.
Is Grifols stock overvalued or undervalued?
On Gekko’s estimate Grifols is undervalued: the Sep 28, 2026 close of $7.41 is 41.7% below Gekko Fair Value of $12.72. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Grifols report earnings next?
Grifols is expected to report on Nov 10, 2026 (42 days away). Analysts expect earnings of $0.30 per share on revenue of $2.29B. Grifols beat the earnings estimate in 1 of its last 8 reports, moving 5% on average across the report.
What is Grifols’s 52-week high and low?
Grifols’s 52-week high is $10.23 and its 52-week low is $6.96; it closed at $7.41 on Sep 28, 2026, −24.1% over the past year. Over the last five years the shares peaked at $15.62 on Sep 28, 2021.
Is Grifols stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Grifols the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.